3 completed, 1 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Flushing: new trials by email Literature Review of Flushing trials Research Report on Flushing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome Octreotide LAR - Neuroendocrine Carcinoma | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 2 | 2013-12-01 | 2015-01-12 |
| Effects of PRK 124 Lotion in Acne Rosacea PRK 124 - Acne Rosacea | Phase 1 / Phase 2 | Completed | University of California, Irvine | 24 | 2007-04-01 | 2014-01-17 |
| MK0524A Phase IIb Study (0524A-011)(COMPLETED) Comparator: niacin / Duration of Treatment: 17 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks - Flushing | Phase 2 | Completed | Merck Sharp & Dohme LLC | 154 | 2004-08-01 | 2015-08-25 |
| Endpoint Validation Study (0524A-015) MK0524A, /Duration of Treatment : 8 Weeks, Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks - Flushing | Phase 2 | Completed | Merck Sharp & Dohme LLC | 165 | 2004-08-01 | 2017-02-17 |
Acne Vulgaris (1) · Carcinoma, Neuroendocrine (1) · Diarrhea (1) · Erythema (1) · Neoplasm Metastasis (1) · Neuroendocrine Tumors (1) · Rosacea (1) · Telangiectasis (1)
Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Skin Manifestations (4) · Acneiform Eruptions (1) · Adenocarcinoma (1) · Carcinoma (1) · Cardiovascular Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neoplastic Processes (1) · Neuroectodermal Tumors (1) · Pathologic Processes (1)
Duration of Therapy (2) · MK-0524 (1) · Niacin (1) · pyratine 6 (1)
Merck Sharp & Dohme LLC (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · University of California, Irvine (1)
United States (2)